In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Announcing its first M&A deal in more than a year, California, USA-based Gilead Sciences said yesterday that it has acquired privately-held US biotech XinThera. 10 May 2023
Biotechnology
Privately-held Chinese biotech Zion Pharma revealed that Swiss pharms giant Roche has acquired the global rights to Zion’s lead program, ZN-A-1041, an orally administered selective tyrosine kinase inhibitor targeting the human epidermal growth factor receptor 2 (HER2). 10 May 2023
Generics
Effective June 1, 2023, prescribing of oral ivermectin for ‘off-label’ uses will no longer be limited to specialists such as dermatologists, gastroenterologists and infectious diseases specialists, in Australia. 10 May 2023
Biotechnology
US biopharma Insmed yesterday announced progress across its early-stage research programs, at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More. 10 May 2023
Biotechnology
In line with a trend for big life science firms to divest non-core operations, medtech giant Baxter International (NYSE: BAX) is to sell off its biopharma manufacturing unit. 10 May 2023
Biotechnology
US drugmaker EQRx had already signalled a shift away from its foundational principle to develop and deliver innovative medicines to patients at radically lower prices. 9 May 2023
Biotechnology
The World Health Organization’s (WHO) declaration on Friday that the COVID-19 global emergency status has ended, and that the virus should now be managed alongside other infectious diseases, formally brings to an end what has been an uncertain and difficult time for much of the world. 9 May 2023
Biotechnology
A new Fabry disease therapy, PRX-102 (pegunigalsidase alfa), has been given marketing authorization by the European Medicines Agency. 9 May 2023
Pharmaceutical
A bumper month of M&A activity in March gave way to one with just three acquisitions in April - albeit two of those were multi-billion dollar deals. 9 May 2023
Biotechnology
Japanese drugmaker Eisai has entered into an agreement with Chinese firm Bliss Biopharmaceutical to develop an antibody-drug conjugate (ADC). 9 May 2023
Biotechnology
Spanish dermatology company Almirall has recorded net sales of 230 million euros ($253 million) in the first quarter of 2023, a 6% increase, and net income of 7.7 million euros. 9 May 2023
Generics
India’s Venus Remedies has won separate marketing authorizations for off-patent cancer drugs in the Philippines and Iraq. 9 May 2023
Pharmaceutical
The UK’s largest drugmaker, AstraZeneca, has secured an additional approval in the USA for its heart med Farxiga (dapagliflozin). 9 May 2023
Pharmaceutical
German drugmaker Bayer (BAYN: DE) has announced the inauguration of its new life science incubator in Kendall Square, Cambridge, Massachusetts. 5 May 2023
Biotechnology
The poor execution of a Phase III trial in Lyme disease has set back plans to submit vaccine candidate VLA15 for regulatory approval in the USA. 5 May 2023
Pharmaceutical
Roche has announced the launch of the Institute of Human Biology (IHB), focussing on advancing research in the field of human model systems such as organoids. 5 May 2023
Biotechnology
US mRNA specialist Moderna has reported first-quarter revenues of $1.86 billion. 5 May 2023
Biotechnology
The UK’s biggest drugmaker, AstraZeneca, has terminated a collaboration with oncolytic virus company Transgene. 5 May 2023
Pharmaceutical
The renegotiation of the UK’s Voluntary Pricing and Access Scheme (VPAS) has begun. 4 May 2023
Biotechnology
Regeneron was trading 7% lower on Thursday lunchtime following the presentation of its first-quarter 2023 financial results and latest guidance for the full-year. 4 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze